Scientists at the University of Louisville School of Medicine in Kentucky have identified a previously unknown molecular target of cannabidiol (CBD), which may have significant therapeutic implications for Parkinson’s Disease (PD).
Our video series Cannabis Conversations interviews Dr. Ethan Russo on clinical endocannabinoid deficiency and ways to target the endocannabinoid system for therapeutic benefit.
New scientific data shows that CBD interacts directly with the CB1 cannabinoid receptor in ways that are therapeutically relevant while modulating the psychoactive effects of THC. CBD lowers the ceiling on the ability of THC and endogenous cannabinoids to stimulate CB1. Cannabidiol is a profound mood-altering substance, even if it may not have a “high”.
Cannabidiol is a safe, non-intoxicating, and non-addictive cannabis compound with significant therapeutic attributes, but CBD-drug interactions may be problematic in some cases.
A groundbreaking study has documented the superior therapeutic properties of whole plant CBD-rich cannabis extract as compared to single-molecule CBD.
By defining cannabinoids as drugs that work at the CB1 and CB2 receptors (the canonical cannabinoid receptors concentrated in the central and peripheral nervous system), researchers may be overlooking beneficial compounds in cannabis that work by other mechanisms.
Cannabidiol (CBD), a non-psychoactive component of the marijuana plant, has generated significant interest among scientists and physicians in recent years—but how CBD exerts its therapeutic impact on a molecular level is still being sorted out.